Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?

about

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

P2860

Q58792995-F24A6957-13D5-42B4-82B3-6A207A4CB92B

P2860

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?

Item

http://www.wikidata.org/entity/Q52691505

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Loss of heterozygosity as a ma ...... a: a role for PARP inhibition?

@en

Loss of heterozygosity as a ma ...... a: a role for PARP inhibition?

@nl

type

Item

label

Loss of heterozygosity as a ma ...... a: a role for PARP inhibition?

@en

Loss of heterozygosity as a ma ...... a: a role for PARP inhibition?

@nl

prefLabel

Loss of heterozygosity as a ma ...... a: a role for PARP inhibition?

@en

Loss of heterozygosity as a ma ...... a: a role for PARP inhibition?

@nl

P1476

Loss of heterozygosity as a ma ...... a: a role for PARP inhibition?

@en

P2093

Andrea Loehr

http://www.w3.org/2001/XMLSchema#string

Faith E Davies

http://www.w3.org/2001/XMLSchema#string

James Sun

http://www.w3.org/2001/XMLSchema#string

Kyle Fedorchak

http://www.w3.org/2001/XMLSchema#string

Ruslana Tytarenko

http://www.w3.org/2001/XMLSchema#string

Shayu Deshpande

http://www.w3.org/2001/XMLSchema#string

Tariq Mughal

http://www.w3.org/2001/XMLSchema#string

P2860

Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.

The molecular classification of multiple myeloma

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors

Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

P2888

s41375-018-0017-0

P304

1561-1566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41375-018-0017-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29467487

http://www.w3.org/2001/XMLSchema#string

P932

6035152

http://www.w3.org/2001/XMLSchema#string

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?

about

P2860

P2860

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932